Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Vivoryon Therapeutics has announced promising results from its Phase 2b study of varoglutamstat, showing significant improvement in kidney function, particularly among diabetic patients. The drug demonstrated an excellent safety profile and may offer a new treatment approach for diabetic kidney disease and other kidney disorders. The company plans further studies to confirm these effects.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
